Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment
1. Eli Lilly's Phase 2 trial of eloralintide showed significant weight reduction. 2. Weight loss ranged from 9.5% to 20.1%, outperforming placebo markedly. 3. Eloralintide improved cardiometabolic risk factors, indicating broad health benefits. 4. Patients experienced higher fatigue compared to other treatments. 5. LLY's stock dropped 2.76% despite promising trial results.